Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.
  • Home
  • About Us
    • Management Team
    • Board of Directors
  • Products in Development
    • TO-2061
  • Investors
    • Press Releases
    • Events & Presentations
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Stock Information
      • Historic Stock Lookup
    • Analysts
    • Shareholder Tools
      • Shareholder Briefcase
      • Email Alerts
  • Careers
  • Contact
 

For more information, please click here »

News & Events

12/21/11
Transcept Pharmaceuticals Receives $10 Million Milestone Payment from Purdue for Listing of Intermezzo Formulation Patents in FDA Orange Book

12/08/11
Transcept Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011

11/30/11
Transcept Pharmaceuticals to Host Conference Call to Discuss Purdue's Exercise of Option to Commercialize Intermezzo® in the United States

In Development

Transcept is developing TO-2061, a low dose form of ondansetron, as an adjunctive therapy in adult patients with obsessive compulsive disorder (OCD) not adequately responsive to currently approved OCD medication.

Click here for more information about TO-2061

Copyright © 2012  |  
Sitemap  |  Contact Us